KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Gains from Investment Securities: 2012-2024

Historic Gains from Investment Securities for Xenon Pharmaceuticals (XENE) over the last 13 years, with Dec 2024 value amounting to $10.7 million.

  • Xenon Pharmaceuticals' Gains from Investment Securities was N/A to -$89,000 in Q3 2025 from the same period last year, while for Mar 2025 it was $12.1 million, marking a year-over-year increase of 13.28%. This contributed to the annual value of $10.7 million for FY2024, which is 20.40% up from last year.
  • Latest data reveals that Xenon Pharmaceuticals reported Gains from Investment Securities of $10.7 million as of FY2024, which was up 20.40% from $8.9 million recorded in FY2023.
  • Over the past 5 years, Xenon Pharmaceuticals' Gains from Investment Securities peaked at $10.7 million during FY2024, and registered a low of $4.8 million during FY2020.
  • Its 3-year average for Gains from Investment Securities is $8.9 million, with a median of $8.9 million in 2023.
  • Data for Xenon Pharmaceuticals' Gains from Investment Securities shows a peak YoY soared of 34.65% (in 2020) over the last 5 years.
  • Xenon Pharmaceuticals' Gains from Investment Securities (Yearly) stood at $4.8 million in 2020, then climbed by 18.48% to $5.6 million in 2021, then grew by 26.24% to $7.1 million in 2022, then increased by 24.96% to $8.9 million in 2023, then increased by 20.40% to $10.7 million in 2024.